

# PRODUCT INFORMATION



## Adenosine 5'-diphosphate (potassium salt hydrate)

Item No. 21121

**Formal Name:** adenosine 5'-(trihydrogen diphosphate),  
monopotassium salt, hydrate

**Synonyms:** Adenosine Pyrophosphate, ADP, 5'-ADP

**MF:** C<sub>10</sub>H<sub>14</sub>N<sub>5</sub>O<sub>10</sub>P<sub>2</sub> • K [XH<sub>2</sub>O]

**FW:** 466.3


**Purity:** ≥95%

**UV/Vis.:** λ<sub>max</sub>: 257 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Adenosine 5'-diphosphate (ADP) (potassium salt hydrate) is supplied as a crystalline solid. Aqueous solutions of ADP (potassium salt hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of ADP (potassium salt hydrate) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

ADP is an adenosine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5' position. It is produced by dephosphorylation of adenosine 5'-triphosphate (ATP; Item No. 14498) by ATPases and can be converted back to ATP by ATP synthases. ADP can also be metabolized to adenosine 5'-monophosphate (AMP; Item No. 21094) and 2'-deoxyadenosine 5'-diphosphate (dADP). ADP can modulate several receptors, activating certain purinergic receptors (EC<sub>50</sub> = 24 nM for P2Y<sub>1</sub>) and inhibiting others (IC<sub>50</sub> = 67 nM for P2X<sub>2/3</sub>), inhibiting rat ecto-5'nucleotidase (K<sub>i</sub> = 0.91 nM), and regulating the phosphorylation status of AMP-activated protein kinase (AMPK).<sup>1-4</sup>

### References

1. Azran, S., Förster, D., Danino, O., *et al.* Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. *J. Med. Chem.* **56**(12), 4938-4952 (2013).
2. Baqi, Y., Lee, S.-Y., Iqbal, J., *et al.* Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. *J. Med. Chem.* **53**(5), 2076-2086 (2010).
3. Jarvis, M.F., Bianchi, B., Uchic, J.T., *et al.* [<sup>3</sup>H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X<sub>2/3</sub> and P2X<sub>3</sub> receptors. *J. Pharmacol. Exp. Ther.* **310**(1), 407-416 (2004).
4. Ruderman, N.B., Carling, D., Prentki, M., *et al.* AMPK, insulin resistance, and the metabolic syndrome. *J. Clin. Invest.* **123**(7), 2764-2772 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/08/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM